

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Acute Otitis Externa / Otitis Media with Effusion (8 measures) (AAO-HNS Foundation)						
AOE: Topical Therapy		X		X	X	
AOE: Pain Assessment		X		X	X	
AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use		X		X	X	
OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility		X		X	X	
OME: Hearing Testing		X		X	X	
OME: Antihistamines or Decongestants – Avoidance of Inappropriate Use		X		X		
OME: Systemic Antimicrobials – Avoidance of Inappropriate Use		X		X		
OME: Systemic Corticosteroids – Avoidance of Inappropriate Use		X		X		
Anesthesiology and Critical Care (3 measures) (ASA)						
Prevention of ventilator-associated pneumonia – head elevation		X		X		
Prevention of catheter-related bloodstream infections (CRBSI) – central venous catheter (CVC) insertion protocol	X (2yr)	X		X	X	
Perioperative temperature management	X (2yr)	X				
Asthma (2 measures)						
Asthma assessment	X	X	X	X	X	
Pharmacologic therapy	X	X	X	X	X	
Atrial Fibrillation and Atrial Flutter (3 measures) (ACC / AHA)						
Assessment of thromboembolic risk factors						
Chronic anticoagulation therapy						
Monthly international normalized ratio (INR) measurement						
Chronic Kidney Disease (6 measures) (RPA)						
Blood Pressure Management (as 2 measures in PQRI 08)		X		X	X	
ACE Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) Therapy		X		X		
Laboratory Testing (Calcium, Phosphorus, PTH and Lipid Profile)		X		X	X	
Plan of Care - Anemia		X		X	X	
Influenza Immunization		X			X	
Referral for AV Fistula		X			X	

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Chronic Obstructive Pulmonary Disease (12 measures)						
Spirometry evaluation	X		X	X	X	
Assessment of symptoms						
Smoking assessment						
Smoking cessation intervention						
Inhaled bronchodilator therapy	X		X	X	X	
Assessment of oxygen saturation	X					
Long term oxygen therapy						
Recommendation of influenza immunization						
Influenza immunization administered						
Assessment of pneumococcus immunization status						
Pneumococcus immunization administered						
Pulmonary rehabilitation: exercise training recommended						
Chronic Stable Coronary Artery Disease (10 measures) (ACC / AHA)						
Blood pressure measurement						X
Lipid profile		X			X	X
Symptom and activity assessment	X					
Smoking cessation (2)						
Antiplatelet therapy	X	X	X	X	X	X
Drug therapy for lowering LDL-cholesterol	X	X				X
Beta-blocker therapy – prior myocardial infarction (MI)	X	X	X	X	X	X
ACE inhibitor or ARB therapy	X	X		X	X	X
Screening for diabetes						
Chronic Wound Care (7 measures) (ASPS)						
Use of wound surface culture technique in patients with chronic skin ulcers (overuse measure)		X				
Use of wet to dry dressings in patients with chronic skin ulcers (overuse measure)		X				
Assessment of wound characteristics in patients undergoing debridement						
Use of compression system in patients with venous ulcers		X			X	
Patient education regarding long term compression therapy		X				
Offloading (pressure relief) of diabetic foot ulcers						
Patient education regarding diabetic foot care		X				

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Community-acquired Bacterial Pneumonia (12 measures)						
Chest radiograph						
Assessment of co-morbid conditions						
Vital signs (also in Emergency Department measure set)				X	X	
Assessment of oxygen saturation (also in Emergency Department measure set)				X	X	
Assessment of mental status (also in Emergency Department measure set)				X	X	
Assessment of hydration status						
Level of care rationale						
Empiric antibiotic (also in Emergency Department measure set)				X	X	
Tobacco use assessment						
Tobacco cessation recommendation						
Assessment of influenza immunization status						
Assessment of pneumococcus immunization status						
Diabetes - Adult (12 measures)						
A1c management						
Lipid management						
Urine protein screening (2)						
Eye examination						
Foot examination						
Influenza immunization (2)						
Blood pressure management		X				
Aspirin use						
Smoking cessation (2)						
Emergency Medicine (9 measures) (ACEP)						
Electrocardiogram performed for non-traumatic chest pain	X (2yr)	X	X	X	X	
Aspirin at arrival for AMI	X (2yr)	X	X	X	X	
Electrocardiogram performed for syncope	X (2yr)	X	X	X	X	
Vital signs for community-acquired bacterial pneumonia	X (2yr)	X	X	X	X	
Assessment for oxygen saturation for community-acquired bacterial pneumonia	X (2yr)	X	X	X	X	
Assessment of mental status for community-acquired bacterial pneumonia	X (2yr)	X	X	X	X	
Empiric antibiotic for community-acquired bacterial pneumonia	X (2yr)	X	X	X	X	

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Fibrinolytic therapy ordered within 20 minutes of ECG performed for AMI (QI)		X				
Care coordination for PCI (QI)		X				
Endoscopy and Polyp Surveillance (3 measures) (AGA / ASGE)						
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients		X				
Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use		X			X	
Comprehensive Colonoscopy Documentation		X				
End Stage Renal Disease - Adult (6 measures) (RPA)						
Influenza vaccination	X (2yr)	X		X	X	
Vascular access – patients receiving hemodialysis		X		X		
Vascular access – patients receiving dialysis with a permanent catheter		X				
Plan of care for anemia		X		X		
Plan of care for inadequate hemodialysis	X (2yr)	X		X	X	
Plan of care for inadequate peritoneal dialysis	X (2yr)	X		X	X	
End Stage Renal Disease - Pediatric (2 measures) (ASPN)						
Plan of care for inadequate hemodialysis		X			X	
Influenza immunization		X			X	
Eye Care (10 measures) (AAO)						
Primary open-angle glaucoma: Optic nerve evaluation	X (2yr)	X	X	X	X	
Primary open-angle glaucoma: Reduction of intraocular pressure by 15% or documentation of a plan of care		X			X	
Primary open-angle glaucoma: Counseling on glaucoma		X				
Age-related macular degeneration : Counseling on Antioxidant Supplements		X	X		X	
Age-related macular degeneration : Dilated macular examination	X (2yr)	X	X	X	X	
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures		X				
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery		X				
Cataracts: Comprehensive Pre-operative Assessment for Cataract Surgery with Intraocular (IOL) Placement		X			X	
Diabetic retinopathy: Documentation of presence or absence of macular edema and level of severity of retinopathy	X (2yr)	X	X	X	X	
Diabetic retinopathy: Communication with the physician managing ongoing diabetes care	X (2yr)	X	X	X	X	

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Gastroesophageal Reflux Disease (5 measures) (AGA Institute)						
Assessment for alarm symptoms		X	X			
Upper endoscopy for patients with alarm symptoms		X	X			
Biopsy for Barrett's esophagus		X	X			
Barium swallow – inappropriate use		X	X			
Continuous medication therapy – assessment of GERD symptoms		X		X		
Geriatrics (9 measures) (AGS)						
Medication reconciliation	X (2yr)	X	X	X	X	
Advance care plan	X (2yr)	X	X	X	X	
Assessment of presence or absence of urinary incontinence in women aged 65 years and older	X (2yr)	X	X	X	X	
Characterization of urinary incontinence in women aged 65 years and older	X (2yr)	X	X	X	X	
Plan of care for urinary incontinence in women aged 65 years and older	X (2yr)	X	X	X	X	
Urinary incontinence – medication overuse in women aged 65 years and older (QI)						
Screening for future fall risk	X (2yr)	X	X	X		
Risk Assessment for Falls		X			X	
Plan of Care for Falls		X			X	
Heart Failure (11 measures) (ACC / AHA)						
Left ventricular function assessment	X	X				X
Weight measurement	X					X
Blood pressure measurement						X
Assessment of clinical symptoms of volume overload (excess)	X					
Assessment of activity level	X					
Assessment of clinical signs of volume overload (excess)						
Patient education	X					X
Beta-blocker therapy	X	X	X	X	X	X
ACE inhibitor or ARB therapy	X	X	X	X	X	X
Warfarin therapy for patients with atrial fibrillation	X	X				X
Laboratory tests						

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Hematology (4 measures) (ASH)						
Myelodysplastic syndrome (MDS) and acute leukemias: Baseline cytogenetic testing performed on bone marrow	X (2yr)	X	X	X	X	
MDS: Documentation of iron stores in patients receiving erythropoietin therapy	X (2yr)	X	X	X	X	
Multiple myeloma: Treatment with bisphosphonates	X (2yr)	X	X	X	X	
Chronic lymphocytic leukemia: Baseline flow cytometry	X (2yr)	X	X	X	X	
Hepatitis C (10 measures) (AGA Institute)						
Testing for chronic hepatitis C (HCV): confirmation of hepatitis C viremia	X (2yr)	X		X	X	
HCV RNA testing before initiating treatment***	X (2yr)	X		X	X	
HCV genotype testing prior to treatment***	X (2yr)	X		X	X	
Antiviral treatment prescribed	X (2yr)	X				
HCV RNA testing at week 12 of treatment	X (2yr)	X		X	X	
Hepatitis A vaccination***	X (2yr)	X		2	X	
Hepatitis B vaccination***	X (2yr)	X		combin ed	X	
Counseling regarding risk of alcohol consumption	X (2yr)	X		X	X	
Counseling regarding use of contraception prior to antiviral treatment	X (2yr)	X		X	X	
HCV RNA testing at week 24 of treatment (Quality Improvement Only)						
HIV / AIDS (17 measures) (IDSA / HIV Med Assoc. / HRSA)						
Medical Visit (System Level and Physician Level)	X (2yr)					
CD4+ Cell Count	X (2yr)				X	
Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	X (2yr)				X	
Adolescent and Adult Patients With HIV/AIDS who are Prescribed Potent Antiretroviral Therapy	X (2yr)				X	
HIV RNA Control for all patients on Potent Antiretroviral Therapy (System Level)						
HIV RNA Control After Six Months of Potent Antiretroviral Therapy	X (2yr)				X	
Tuberculosis (TB) Screening	X (2yr)					
Sexually Transmitted Diseases-Chlamydia and Gonorrhea Screenings	X (2yr)					
Sexually Transmitted Diseases-Syphilis Screening	X (2yr)					
Other Infectious Diseases-Hepatitis B Screening	X (2yr)					
Other Infectious Diseases-Hepatitis C Screening	X (2yr)					
Influenza Immunization						
Pneumococcal Immunization						
Hepatitis B Vaccination	X (2yr)					
Hepatitis B Vaccination (System Level)						
Screening for Injection Drug Use	X (2yr)					
Screening for High Risk Sexual Behaviors	X (2yr)					

† - Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Hypertension (2 measures) (ACC / AHA)						
Blood pressure measurement	X					X
Plan of care	X					X
Major Depressive Disorder - Adult (5 measures)						
Diagnostic evaluation	X	X		X	X	
Suicide assessment	X	X		X	X	
Severity classification						
Treatment: Psychotherapy, medication management, and/or electroconvulsive therapy						
Continuation of antidepressant medication						
Major Depressive Disorder - Child and Adolescent (6 measures) (APA)						
Interview of Adolescent or Child						
Diagnostic Evaluation						
Suicide Risk Assessment						
Psychotherapy						
Medications Considered						
Follow-Up Care						
Melanoma (4 measures) (AAD)						
Melanoma Follow-Up Measures		X			X	
Melanoma Continuity of Care – Recall System		X			X	
Melanoma Coordination of Care		X			X	
Overutilization of Imaging Studies in Stage 0-1A Melanoma		X				
Nuclear Medicine (2 measures) (Society of Nuclear Medicine)						
Correlation With Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	X (2yr)	X			X	
Communication to Referring Physician of Patient's Potential Risk for Fracture for All Patients Undergoing Bone Scintigraphy						
Obstructive Sleep Apnea (4 measures) (AASM / AAN / ACCP / AAOHNS / APA)						
Assessment of Sleep Symptoms						
Severity Assessment at Initial Diagnosis						
Positive Airway Pressure Therapy Prescribed						
Adherence to Positive Airway Pressure Therapy						

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Oncology (10 measures) (ASTRO/ASCO)						
Cancer stage documented	X (2yr)	X				
Hormonal therapy for stage IC through IIIC, ER/PR positive breast cancer	X	X		X	X	
Chemotherapy for Stage IIIA-Stage IIIC colon cancer patients	X (2yr)	X		X	X	
Plan for chemotherapy documented		X		X		
Treatment summary documented and communicated – Medical Oncology (Quality Improvement Only)						
Treatment summary communicated – Radiation Oncology	X (2yr)	X				
Normal tissue dose constraints specified	X (2yr)	X			X	
Pain Intensity Quantified***	X (2yr)	X			X	
Plan of Care for Pain***	X (2yr)	X			X	
Pathology report (Quality Improvement Only)						
Osteoarthritis (7 measures) (AAOS)						
Symptom and functional assessment	X	X		X	X	
Physical examination of the involved joint						
Assessment for use of anti-inflammatory or analgesic OTC medications	X	X			X	
Anti-inflammatory/analgesic therapy						
Non-steroidal anti-inflammatory drug (NSAID) risk assessment						
Gastrointestinal prophylaxis						
Therapeutic exercise for the involved joint						
Osteoporosis (6 measures) (AAFP / AAOS / AACE / ACR / TES)						
Communication with the physician managing on-going care post fracture	X (2yr)	X	X	X	X	
Screening or therapy for women aged 65 years and older	X (2yr)	X	X	X	X	
Management following fracture	X (2yr)	X	X	X	X	
Pharmacological therapy	X (2yr)	X	X	X	X	
Counseling for vitamin D, calcium intake and exercise		X	X			
Glucocorticosteroids and other secondary causes (QI)						
Outpatient Parenteral Antimicrobial Therapy (5 measures) (IDSA)						
Plan of care documentation at initial visit (QI)						
Maintenance visit – history (QI)						
Maintenance visit – physical examination (QI)						
Laboratory testing – CBC (QI)						
Laboratory testing – creatinine or GFR (QI)						

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Palliative Care (2 measures)						
Advance care planning						
Dyspnea screening and dyspnea management		X				
Pathology (2 measures) (CAP)						
Breast cancer resection pathology reporting – pT category and pN category with histologic grade	X (2yr)	X		X	X	
Colorectal cancer resection pathology reporting – pT category and pN category with histologic grade	X (2yr)	X		X	X	
Pediatric Acute Gastroenteritis (4 measures) (AAP / AAFP)						
Documentation of hydration status						
Weight measurement						
Recommendation of appropriate oral rehydration solution						
Education						
Perioperative Care (6 measures) (ACS)						
Timing of prophylactic antibiotics – ordering physician	X (2yr)	X	X	X	X	
Timing of prophylactic antibiotics – administering physician	X (2yr)	X	X	X	X	
Selection of prophylactic antibiotic – first or second generation cephalosporin	X (2yr)	X	X	X	X	
Discontinuation of prophylactic antibiotics (non-cardiac procedures)	X (2yr)	X	X	X	X	
Discontinuation of prophylactic antibiotics (cardiac procedures)	X (2yr)	X	X	X	X	
Venous thromboembolism (VTE) prophylaxis	X (2yr)	X	X	X	X	
Prenatal Testing (2 measures)						
Anti-D immune globulin	X	X				
Screening for human immunodeficiency virus	X	X				

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Preventive Care and Screening (11 measures)						
Tobacco use : Queried about tobacco use (2001)	X	X		X	X	
Tobacco use : Tobacco users who received cessation intervention (2001)	X					
Colorectal cancer screening assessment : Colorectal cancer screening (2001)						
Adult influenza immunization: Influenza immunization received (2001)	X			X	X	
Screening mammography: Female patients who received a mammogram (2001)						
Tobacco use: Screening & Cessation Intervention (2008)						
Unhealthy Alcohol Use-Screening (2008)		X			X	
Cervical Cancer Screening (2008)						
Pneumococcal Immunization (2008)						
Obesity Screening (2008)						
Unhealthy Alcohol Use-Screening & Brief Counseling (QI) (2008)						
Prostate Cancer (6 measures) (AUA)						
Initial evaluation		X		X		
Initial evaluation – new diagnosis		X				
Overuse measure – bone scan for staging low-risk patients	X (2yr)	X		X	X	
Treatment options for patients with clinically localized disease		X		X		
Adjuvant hormonal therapy for high-risk patients	X (2yr)	X		X	X	
Three-dimensional radiotherapy	X (2yr)	X		X	X	
Radiology (8 measures) (ACR)						
Stenosis measurement in carotid imaging reports	X (2yr)	X				
Mammography assessment category data collection		X				
Inappropriate use of "probably benign" assessment category in mammography screening	X (2yr)	X			X	
Communication of suspicious findings from the diagnostic mammogram to the practice managing ongoing care		X				
Communication of suspicious findings from the diagnostic mammogram to the patient		X				
Reminder system for mammograms	X (2yr)	X				
CT radiation dose reduction		X				
Exposure time reported for procedures using fluoroscopy	X (2yr)	X			X	

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.

Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report

PCPI performance measure ¹ (# of measures) (Lead Society)	NQF endorsed	AQA selected	PQRI			CMS PGP Demo**
			2007	2008	2009†	
Rheumatoid Arthritis (5 measures) (ACR)						
Tuberculosis Screening		X			X	
Periodic Assessment of Disease Activity		X			X	
Functional Status Assessment		X			X	
Assessment and Classification of Disease Prognosis		X			X	
Glucocorticoid Management		X			X	
Stroke and Stroke Rehabilitation (9 measures) (AAN / ACR)						
Deep vein thrombosis (DVT) prophylaxis for ischemic stroke and intracranial hemorrhage	X (2yr)	X	X	X	X	
Discharged on antiplatelet therapy	X (2yr)	X	X	X	X	
Anticoagulant therapy prescribed for atrial fibrillation	X (2yr)	X	X	X	X	
Tissue plasminogen activator (t-PA) considered	X (2yr)	X	X	X	X	
Screening for dysphagia	X (2yr)	X	X	X	X	
Consideration of rehabilitation services	X (2yr)	X	X	X	X	
Carotid imaging reports	X (2yr)	X	X	X	X	
CT or MRI reports	X (2yr)	X	X	X	X	
Avoidance of intravenous heparin (overuse measure) (QI)						
Substance Use Disorders (3 measures) (APA)						
Counseling regarding psychosocial and pharmacologic treatment options for alcohol dependence		X				
Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Opioid Addiction		X				
Screening for depression among patients with substance abuse or dependence		X				

TOTAL Measure Sets: 42

TOTAL MEASURES: 266

AQA Selected: 150

NQF Endorsed: 111

Notes:

1 – The PCPI is currently evaluating the use of the phrases ‘overuse,’ ‘under use,’ ‘appropriate’ and ‘inappropriate’ in measure names. Measure names may be changed to ensure usage of these terms is consistent and precise.

QI = Quality Improvement Only;

** CMS PGP Demo = CMS Physician Group Practice Demonstration Project

*** Measures are paired--see measure worksheets for details.